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isolated and grown in cultures. In 12 experiments, cocaine, 10 -8 to 10 -6 M or vehicle-con- 
trol, in the absence or presence of metoprolol or phentolamine, was added to each cul- 
ture on day 2 and cells harvested on day 5. In 12 separate experiments, cocaine 10 -6 M, 
cocaine 10-6 M plus the PKC inhibitor bisindolylmaleimide, 10-6 M, or vehicle were added 
to each culture for a mean of 5 mine. then cells were harvested. We determined myocyte 
total protein and myosin heavy chain protein content, and the presence of PKC isozymes 
in cytosol and particulate (nuclear) fractions. PKC translocation from cytosol to particu- 
late fractions indicates PKC activation. RESULTS: Cocaine, 10 -6 M, increased myocyte 
protein content by 28% (p<0.001) and fetal ~-myosin heavy chain protein content/cell by 
82% (p<0.001) but decreased adult (x-myosin heavy chain protein content. Neither beta- 
nor alpha-adrenergic blockade inhibited this process. We found that adult ventricular 
myocytes contain alpha (~), delta, epsilon, and zeta PKC isozymes. Cocaine, 10 "s M, 
increased c~PKC by 37% (p<0.001) in the particulate fraction, decreased (xPKC in the 
cytosol fraction, and increased myocyte protein content by 22% (p<0.01) . In separate 
experiments, c~PKC stimulated rat myocyte ~-myosin heavy chain promoter and 
increased ~-myosin heavy chain protein transcription 3-fold. Addition of bisindolylmaleim- 
ide, 10 -6 M, to myocyte cultures, prevented the cocaine-induced translocation of ~PKC to 
the particulate fraction and cocaine-induced increase in myocyte protein content. CON- 
CLUSIONS: Cocaine increases myocyte protein content by PKC mechanisms. Protein 
kinase C translocation and nuclear transcription factor phosphorylation are important in 
the cardiac hypertrophy and myopathy resulting from chronic cocaine use. 
1178-84 Cardiac Fibroblast Actions of Cardiotrophin-1 and Its 
Receptor Complex with Crosstalk With the Endothelin 
System In Vitro: Modulation by Early Dilated 
Cardiomyopathy 
Toshihiro Tsuruda, Brenda Huntley, Guido Boerrigtar, Alessandro Cataliotti, Shang C. 
Lee, Horng H. Chen, Lisa C. Costello, John C. Burnett, Jr., Mayo Clinic, Rochester, 
Minnesota. 
Background: The cardiac interstitium and its tibrillar collagen matrix play a critical role in 
determining cardiac function and structure. Cardiotrophin-1 (CT-1) is a potent hyper- 
trophic factor in cardiomyocytes, and its gene expression is up-regulated in severe heart 
failure. To date, the role of CT-1 on cardiac fibroblast function is unknown. This study was 
designed to clarify the actions of CT-1 with its receptors, glycoprotein 130 (gp130) and 
leukemia inhibitory factor receptor (LIFR), and elucidate possible crosstalk with the 
endothelin-1 (ET-1)/endothelin type A (ETA) receptor axis in adult canine cardiac fibro- 
blasts (CCF). In addition, we investigated the modulation of these proteins in ventricular 
myocardium from normal dogs and those with tachycardia-induced early dilated cardi- 
omyopathy (EDCM). 
Methods and Results: We assessed DNA synthesis of cardiac fibroblasts by [3H]thymi- 
dine incorporation into cells. Recombinant CT-1 (P<0.01) stimulated DNA synthesis 
between 10 "11 and 10-6 mol/L, with maximal effect at 10-6 mol/L (186%). Administration 
(10 pJmL) of gp130 or LIF receptor antibody (P<0.01) completely inhibited not only CT-1 
stimulated DNA synthesis in CCF but also ET-1 stimulated DNA synthesis. By contrast, 
10 -5 mol/L BQ123, an ET A receptor antagonist, abolished CT-1 as well as ET-1 stimu- 
lated DNA synthesis. Western Blotting showed that 10 .7 mol/L ET-1 stimulated the trans- 
location of LIFR from cytosol to the cell membrane. CT-1 and gp130/LIFR in a canine 
model of EDCM produced by progressively increasing pacing rates (180 to 200 bpm for 
approximately 14-20 days) were characterized by immunohistochemistry as compared to 
normal ventricular myocardium. Staining revealed that CT-1 and gp130 were decreased 
and LIFR were enhanced. 
Conclusions: This study demonstrates that CT-1 and its receptor complex are function- 
ally important and contribute to cardiac fibroblast activation. In addition, CT-1 stimulation 
in CCF involves crosstalk with the gp13O/LIF receptor complex and the ET-1/ET A recep- 
tor. The in vivo findings of decreased CT-1 protein and gp130 in a model of EDCM also 
suggest that an impairment of this axis could contribute to progressive cardiac dilatation. 
1178-85 Oxidized LDL Through LOX-1 Increases the Expression 
of Angiotensin Converting Enzyme in Human Coronary 
Artery  Endothelial Cells 
Robin M Sinah, Dayuan Li, Ling Liu, Hongjiang Chen, Francesco Romeo, Nelly Kazzaz, 
Ballkrishna M. Singh, Jawahar L, Mehta, University of Arkansas for Medical Sciences, 
Little Rock, Arkansas, Central Arkansas Veterans Healthcare System, Little Rock, 
Arkansas. 
Background and objectives: Abnormalities of both renin-angiotensin system (RAS) and 
lipide play a critical role in the pathogenesis of cardiovascular diseases. Our previous 
studies demonstrate that angiotensin II (Ang II) and oxidized low-density lipoprotein (ox- 
LDL) in a synergistic fashion induce vascular endothelial injury. This study was con- 
ducted to examine the modulation of ACE gene expression by ox-LDL in human coronary 
artery endothelial cells (HCAECs). 
Methods and results: HCAECs were cultured and incubated with ox-LDL (10 to 80 rag/ 
ml) for 3-24 hours. Ox-LDL increased the expression of mRNA (determined by semi- 
quantitative RT-PCR) and prote!n (determined by Western blot) of ACE in a concentra- 
tion- and time-dependent fashion. Native-LDL had no effect on the expression of ACE 
gene. These effects of ox-LDL was mediated by its endothelial receptor LOX-1, since 
pretreatment of HCAECs with the blocking antibody to LOX-1 (10 mg/ml) prevented the 
expression of ACE (P<0,01 vs. control) in response to ox-LDL. In parallel experiments, 
HCAECs were treated with the mitogen-ectivated protein kinase (MAPK) inhibitor 
(PD98059, 10 raM) for 30 rain and then exposed to ox-LDL MAPK inhibitor blocked the 
effects of ox-LDL on the expression of ACE (P<0.01 vs. ox-LDL group). In other experi- 
ments, we observed that pretreatment of HCAECs with simvastatin (10 mM) attenuated 
ox-LDL-induced ACE gene expression (P<0.01 vs. ox-LDL alone). 
Conclusions: These observations provide a novel mechanism of interaction between 
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RAS and ox-LDL (upregulation of ACE via LOX-1 activation). MAPK activation plays a 
critical signal transduction role in this process. Lastly, statins can modulate ACE expres- 
sion by ox-LDL. 
1178-86 Activation of the Tissue Endothelin System in Severe 
Polyglobulis 
Matthias Hermann. Frank Ruschitzka, Thomas Quaschning. Sidney Shaw, Henning 
Morawietz, Berthold Hocher, Max Gassmann, Thomas F. L~scher, Cardiovascular 
Research, University of Zuerich, Zuerich, Switzerland, Cardiovascular Center, University 
Hospital Zuerich, Zuerich, Switzerland. 
We generated a novel erythropoietin overexpressing mouse, which reaches adulthood 
despite hematocrit levels of about 80%. The role of endothelin in severe polyglobulia, 
however, remains still to be determined. In this novel transgenic model of severe poly- 
globulia, we analyzed endothelin-1 (ET-1) promoter activity, ET-1 immuno-histochemis- 
try, ET-l-protein tissue levels, ETA/B-receptor subtype mRNA expression and vascular 
reactivity to ET-I. 
Transgenic polyglobulic animals xhibited increased ET-1 promoter activity (P<0.05 vs. 
wildtype controls) and ET-1 tissue levels in heart (265±36 vs. 165±25 pg/mg tissue; 
P<0.05 for left ventricle and 320±38 vs.170±31 pg/mg tissue; P<0.O5 for right ventricle, 
respectively), renal cortex (793±67 vs. 395±32 pg/mg tissue; P<0.01), and aorta (2.2-.~0.3 
vs. 0.5±0.1 pg/mg tissue; P<0.01). Aortic ET receptor subtype mRNA expression was 
enhanced in transgenic animals (1.5±0.2 vs.1.0±0.2 RU for ETA; 1.2¢0.1 vs. 0.7±0.1 RU 
(P<0.05) for ETB receptor mRNA, respectively). Vascular reactivity to ET-1 was reduced 
(35±5% vs. 78¢7% of KCI; P<0.05), but increased by preincubation with the nitric oxide 
(NO) synthase inhibitor L-NAME (P<0.05), thus indicating that the vascular effects of ET- 
1 are offset by NO, the endothelial counterpart of ET-1, in vivo. Correspondingly, treat- 
ment with the ETA receptor antagonist darusentan prolonged survival of transgenic mice 
exposed to the NO synthase inhibitor L-NAME (p<0.01). We here for the first time dem- 
onstrate that polyglobulia induces a marked activation of the tissue endothelin system. 
Since treatment with darusentan prolonged survival after acute NO blockade, activation 
of the tissue endothelin system may thus advance as a new target in the treatment of 
cardiovascular disease associated with severe polyglobulia. 
POSTER SESS ION 
1179 Improving Screening and Lipid Treatment 
to Prevent Coronary Heart Disease 
Tuesday, March 19, 2002, Noon-2:00 p.m. 
Georgia World Congress Center, Hall G 
Presentation Hour: Noon-l:00 p.m. 
1179-75 Calculated LDL Cholesterols Frequently Underestimate 
Directly Measured LDL Determinations in Patients With 
Triglyceride Levels _<400 mg/dL 
Dennis A. Tiohe. Ira S. Ockene, George Reed, University of Massachusetts Medical 
Center, Worcester, Massachusetts. 
Elevated low density lipoprotein (LDL) cholesterol is a risk factor for development of cor- 
onary artery disease (CAD). Recent guidelines detail specific LDL cutpoints for risk 
assessment. In clinical practice LDL concentration is usually calculated (C-LDL) from the 
Friedewald formula (FF). Methods: To assess the accuracy of C-LDL by the FF com- 
pared to directly measured LDL (D-LDL), we analyzed 1618 fasting lipid samples 
obtained in 661 patients (pts) [mean age 46+12 yr, 52% female] without overt CAD. Pts 
with triglycerides (TG) >400 mg/dL were excluded. Results: Mean total cholesterol was 
246+41, HDL 52+15, and TG 147+77 mg/dL. C-LDL and D-LDL were significantly differ- 
ent (165_+34 vs 187+41, p<0.0001) and D-LDL exceeded C-LDL in 93% of measure- 
ments. Although C-LDL and D-LDL were related (r=0.90), the discrepancy between C- 
LDL and D-LDL (LDL-difference) increased linearly with TG (r=0.67, figure) and clinically 
important differences existed at normal or slightly elevated TG levels. Regression analy- 
sis indicated that this LDL difference increased by 17 mg/dL for every 100 mg/dL TG 
increase. Conclusions: (1) Significant differences between C-LDL and D-LDL existed in 
pts with TG <400 mg/dl. (2) These differences were related to TG. (3) C-LDL by the FF 
may be unreliable to accurately categorize cardiac risk. 
